ProMIS Neurosciences Technologies Hold Promise for New Alzheimer’s Therapy

ProMIS Neurosciences Technologies Hold Promise for New Alzheimer’s Therapy
ProMIS Neurosciences reported progress of drug discovery technologies at the recent Alzheimer’s Association International Conference (AAIC) meeting, held in Toronto, Canada, showing that the technologies specifically target certain forms of amyloid-beta and tau in Alzheimer’s disease. The company works to identify structures on the surface of the toxic variants of misfolded amyloid-beta, crucial for Alzheimer's, using two proprietary complementary technologies called ProMIS and Collective Coordinates. The methods use computer and thermodynamic calculations to identify the structures, referred to as epitopes by scientists. The first presentation at AAIC, by ProMIS’ chief physics officer Dr.St
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *